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Abstract
Breast cancers show a lack of response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), 
despite 30% of tumors expressing EGFR. The mechanism of this resistance is unknown; however, we have recently 
shown that Met kinase activity compensates for loss of EGFR kinase activity in cell culture models. Met has been 
implicated in the pathogenesis of breast tumors and therefore may cooperate with EGFR for tumor growth. Here we 
have found that EGFR phosphorylation and cell proliferation is in part regulated by Met expression. In addition, we 
found that Met constitutive phosphorylation occurred independent of the Met ligand hepatocyte growth factor (HGF). 
Ligand-independent Met phosphorylation is mediated by Met amplification, mutation, or overexpression and by Met 
interaction with other cell surface molecules. In SUM229 breast cancer cells, we found that Met was not amplified or 
mutated, however it was overexpressed. Met overexpression did not directly correlate with ligand-independent Met 
phosphorylation as the SUM229 cell line was the only Met expressing breast cancer line with constitutive Met 
phosphorylation. Interestingly, Met expression did correlate with EGFR expression and we identified an EGFR/Met 
complex via co-immunoprecipitation. However, we only observed Met constitutive phosphorylation when c-Src also 
was part of this complex. Ligand-independent phosphorylation of Met was decreased by down regulating EGFR 
expression or by inhibiting c-Src kinase activity. Lastly, inhibiting EGFR and Met kinase activities resulted in a synergistic 
decrease in cell proliferation, supporting the idea that EGFR and Met functionally, as well as physically interact in breast 
cancer cells to regulate response to EGFR inhibitors.
Introduction
Epidermal growth factor receptor (EGFR) is a tyrosine
kinase receptor shown to be mechanistically involved in
cell growth and survival (reviewed in [1]). Ligand activa-
tion of EGFR results in homo- and hetero-dimerization
with other members of the EGFR family of receptor
(reviewed in [1]). This dimerization enables EGFR to
autophosphorylate, resulting in the recruitment of signal-
ing proteins to the receptor (reviewed in [1]). Approxi-
mately 30% of human breast tumors overexpress EGFR,
and this overexpression correlates with a loss of estrogen
responsiveness and a poor prognosis [2-5]. Despite
strong correlative evidence from human breast tumors,
transgenic mouse models have clearly demonstrated that
overexpression of the EGFR alone is insufficient for
tumor formation [6]. EGFR tyrosine kinase inhibitors
(TKIs) are in clinical use in lung and pancreatic cancers,
but have yet to demonstrate efficacy in breast cancer. We
and others have recently identified the receptor tyrosine
kinase Met as a key regulator of EGFR tyrosine kinase
inhibitor resistance in cancer [7,8].
Met also is overexpressed in breast cancer cells and
human breast tumors and its expression correlates with
EGFR expression in basal type breast cancers [9-11]. Met
or hepatocyte growth factor receptor is characterized as a
receptor tyrosine kinase [12]. However, unlike EGFR,
there are two broad mechanisms of Met activation:
ligand-dependent and ligand-independent. In the mam-
mary gland, ligand-dependent activation of Met involves
the paracrine production of HGF by stromal cells, includ-
ing fibroblasts [13]. Ligand-independent activation of
Met has been shown to occur through a number of mech-
anisms, including mutation of Met, constitutive
dimerization of Met associated with overexpression,
pathway activation via hypoxic conditions, transactiva-
tion by other membrane proteins (including EGFR), and
loss of negative regulators [14].
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Met, in part, regulates EGFR tyrosine phosphorylation
and growth in the absence of EGFR tyrosine kinase activ-
ity. Here we have identified a physical and functional
interaction between EGFR and Met. Specifically, we
found that EGFR tyrosine phosphorylation and growth
were in part dependent on the expression of Met. We also
found that neither HGF mRNA nor protein was
expressed, suggesting a ligand-independent mechanism
of Met phosphorylation. In that regard, Met was not
amplified or mutated in SUM229 cells. The protein
expression of Met was increased in the SUM229 cells, yet
an increase in protein expression did not correlate with
ligand-independent Met phosphorylation. Instead, we
found that EGFR and Met co-immunoprecipitated in the
SUM229 cells both in the absence and in presence of gefi-
tinib and down regulation of EGFR expression decreased
Met constitutive phosphorylation, again supporting a
physical and functional interaction between EGFR and
Met. Interestingly, c-Src was part of the EGFR/Met com-
plex when Met was constitutively phosphorylated and
inhibiting c-Src kinase activity also decreased Met phos-
phorylation. Taken together, these data suggest that
EGFR and Met interact both physically and functionally
and that the interaction is independent of the kinase
activities of both molecules and that this interaction pro-
motes EGFR TKI resistance via constitutive phosphoryla-
tion of Met.
Results
Met expression regulates EGFR tyrosine phosphorylation 
and growth in the presence of gefitinib
We have previously shown that constitutive phosphoryla-
tion of Met contributes to EGFR TKI resistance in breast
cancer and that decreasing Met kinase activity, decreased
EGFR tyrosine phosphorylation and proliferation in the
presence of an EGFR tyrosine kinase inhibitor [7]. How-
ever, to determine if the expression of Met is required for
EGFR tyrosine phosphorylation and growth in the pres-
ence of EGFR TKIs, we used lentiviral encoding shRNA
constructs targeting Met. Using this method, we were
able knockdown Met to approximately 40% of its endoge-
nous expression level (Fig. 1A; Met panel). When these
cells containing the knocked down Met were analyzed for
EGFR tyrosine phosphorylation in the presence of EGFR
TKIs, we observed a decreased in EGFR tyrosine phos-
phorylation (Fig. 1A; PTyr panel). This decrease in EGFR
overall tyrosine phosphorylation appeared to be medi-
ated by a decrease in the phosphorylation of tyrosines
1068, 1148, and 1173 (Fig. 1A). Importantly, when the
Met knockdown cells were analyzed for cell proliferation
in the presence of gefitinib, an 80% decrease in cell prolif-
eration was observed (Fig. 1B). These data suggest that
downregulating Met expression sensitizes cells to EGFR
TKIs by decreasing EGFR tyrosine phosphorylation and
proliferation.
Met is not genomically amplified but is overexpressed in 
EGFR expressing breast cancer cells
The mechanism of Met constitutive phosphorylation in
SUM229 breast cancer cells is unknown. It was previously
reported that under conditions of acquired resistance to
gefitinib in a lung cancer cell line, Met becomes genomi-
cally amplified and overexpressed [8]. Therefore, we ana-
lyzed array comparative genomic hybridization data to
determine if Met was amplified in the SUM229 cells
[15,16]. We found that Met was not amplified in SUM229
cells as determined by statistical analysis using circular
binary segmentation, which indicated that, the copy
number of MET was not more than 1.3 fold (data not
shown). In addition, we sequenced the Met juxtamem-
brane and kinase domain regions previously shown to be
mutated and mediate constitutive activation of Met in
renal cancers [17]. No mutations were detected in Met
from cDNA prepared from SUM229 cells (data not
shown). Lastly, to determine if Met protein expression
was increased in SUM229 cells we compared protein
Figure 1 Met expression mediates EGFR tyrosine phosphoryla-
tion and proliferation in the absence of EGFR kinase activity. (A) 
SUM229 cells were infected with lentiviral particles containing Met 
shRNA or a non-silencing shRNA for 72 hrs. Cells were treated with ge-
fitinib for the last hour of infection at 0.5 μM, cells were lysed, and 
lysates were immunoprecipitated with anti-EGFR. Immunoprecipitates 
were immunoblotted with anti-EGFR, anti-Ptyr, and the indicated 
phospho-specific sites on the EGFR. Corresponding whole cell lysates 
were immunoblotted with anti-Met and β-actin as a loaded control. 
Through quantification, EGFR phosphorylation was decreased by 53% 
in the gefitinib treated cells and 88% in the gefitinib with Met knocked 
down cells. The two bands in the Met immunoblot represent pro-
cessed and pro-forms of Met. (B) SUM229 cells were infected with len-
tiviral particles containing Met shRNA in the presence of gefitinib or a 
non-silencing control for seven days in the presence of puromycin to 
select for infected cells. Cells were counted using a Coulter Counter 
and the day 8 values were graphed with the error bars representing 
SEM.
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twenty breast cancer cell lines and two non-malignant
mammary epithelial cell lines (Fig. 2A). From this analy-
sis, we found that Met protein was expressed in 50% of
the breast cancer cell lines, yet only the SUM229 cell line
contained constitutively phosphorylated Met (Fig. 2B).
Met constitutive phosphorylation occurs independent of 
ligand in EGFR TKI resistant breast cancer cells
To determine if constitutive phosphorylation of Met is
mediated by its ligand, HGF, we first determined the
amount of HGF present in SUM229 cells from both cell
lysates and conditioned media. We were unable to detect
HGF expression either in the cell lysate (Fig. 3A) or in
conditioned media (Fig. 3B). Lysates and conditioned
media from cells engineered to overexpress HGF were
used as positive controls (Figs. 3A and 3B). These results
were not unexpected, as HGF is not normally produced
as an autocrine factor in normal epithelial nor in carcino-
mas [18]. However, to eliminate the possibility of a small
amount of HGF contributing to the constitutive phos-
phorylation of Met, we used an HGF neutralizing anti-
body to prevent HGF from binding to Met. In the
SUM149 cells where Met is not constitutively phosphory-
lated, we added exogenous HGF to stimulate Met phos-
phorylation and found that the neutralizing antibody
decreased HGF-mediated Met tyrosine phosphorylation
(Fig. 4; left panel). Yet in the SUM229 cells where Met is
constitutively phosphorylated, the HGF neutralizing anti-
body had no effect on Met phosphorylation (Fig. 4; right
panel). Therefore, Met is activated by a ligand-indepen-
dent mechanism in SUM229 cells.
EGFR associates with Met in EGFR TKI resistant breast 
cancer cells
Ligand-independent activation of Met has been shown to
occur through association with co-receptors. These co-
receptors include molecules involved in adhesion, such as
integrins and CD44, receptors known as semiphorins or
plexins, and receptor tyrosine kinases, such as EGFR and
Ron [19]. Therefore, to determine if EGFR and Met have
the ability to co-associate, we immunoprecipitated lysates
from SUM149 or SUM229 cells using EGFR or Met anti-
bodies (as well as an isotype antibody control) and immu-
noblotted using EGFR or Met antibodies. We found that
EGFR and Met did indeed co-immunoprecipitate both in
SUM149 and SUM229 cells (Fig. 5A). Our previous work
found that Met contributed to EGFR tyrosine phosphory-
lation in the presence of an EGFR TKI [7]. We hypothe-
sized that this was a direct phosphorylation that occurred
Figure 2 Met is not amplified, but is overexpressed at the protein 
level. (A) Lysates from the indicated breast cancer cell lines was pre-
pared and 100 ug of protein was separated by SDS-PAGE, transferred, 
and immunoblotted with anti-EGFR, anti-Met, and anti-β-actin. (B) 
Lysates from the Met expressing breast cancer cell lines were immuno-
precipitated with anti-Met antibodies. Immunoprecipitates were sepa-
rated by SDS-PAGE, transferred, and immunoblotted with anti-pMet 
antibodies.
Figure 3 HGF is not expressed in SUM229 breast cancer cells. (A) 
Lysates from SUM149 and SUM229 and conditioned media from RMF-
HGF cells were immunoblotted with anti-HGFα. Recombinant HGF 
was used as a positive control. (B) Conditioned media was collected 
from confluent SUM149, SUM229, and RMF-HGF cell cultures. Diluted 
conditioned media was analyzed for HGF expression using ELISA with 
RMF-HGF as a positive control. The amount of HGF produced from the 
SUM149 and SUM229 lysates was undetectable.
Figure 4 Met phosphorylation occurs independent of ligand. 
SUM149 and SUM229 cells were treated with increasing concentra-
tions of anti-HGF neutralizing antibody. The SUM149 cells were stimu-
lated with 50 ng/ml HGF to induce Met phosphorylation. Whole cell 
lysates were immunoblotted with anti-phospho-Met.
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we treated SUM149 and SUM229 cells with gefitinib and
repeated the co-immunoprecipitation experiment. As
predicted, we found that EGFR and Met remained associ-
ated independent of EGFR tyrosine kinase activity (data
not shown). These results suggest that Met may be medi-
ating EGFR phosphorylation through co-association
leading to conformation changes in both receptors and
that the association between EGFR and Met may regulate
the kinase activity of Met. However, because this associa-
tion is observed in cells without ligand-independent Met
phosphorylation we looked for another kinase associating
with the EGFR/Met complex in SUM229 cells. We identi-
fied c-Src associating with the EGFR in the immunopre-
cipitation complex in the SUM229 cells, but not the
gefitinib sensitive SUM149 cells (Fig. 5A). These data
complement our previous studies demonstrating a role
for c-Src in phosphorylating EGFR in the absence of
EGFR kinase activity [7].
To determine if the formation of the co-precipitation
complex was regulating ligand-independent Met phos-
phorylation, we used shRNA to downregulate EGFR
expression and found that decreasing EGFR expression,
thereby decreasing EGFR and Met association, reduced
Met phosphorylation (Fig. 5B). In addition, inhibiting c-
Src kinase activity with the small molecule kinase inhibi-
tor dasatinib also reduced Met phosphorylation (Fig. 5C).
Therefore, it can be concluded that breaking apart the
EGFR/Met association and reducing the contribution of
c-Src kinase activity by decreasing EGFR expression,
diminished Met constitutive phosphorylation. Thus,
decreasing EGFR expression should abrogate the growth
of SUM229 cells. In fact, knocking down EGFR expres-
sion decreased cell proliferation over a 7-day period by
80% (Fig. 5D). These data suggest that EGFR has the abil-
ity to act as a scaffolding protein to link Met and c-Src.
EGFR and Met inhibitors act synergistically to abrogate 
EGFR TKI resistant breast cancer cell growth
The association of EGFR and Met and their mutual regu-
lation of each other in the absence of EGFR kinase activ-
ity and Met ligand suggests that inhibiting the kinase
activity of the molecules individually may be insufficient
to abrogate cell growth. We previously published prolifer-
ation assays with the combination of EGFR and Met
inhibitors and found when SUM229 cells were treated
with this combination of inhibitors, cell proliferation was
arrested [7]. However, we did not determine if this
decrease in cell proliferation was a result of synergism
between the two drugs. Therefore, we used cell viability
assays to assess the IC50 values for gefitinib and SU11274
(a Met inhibitor) and performed synergy analysis using
an isobologram. We found the calculated IC50 for gefi-
tinib to be approximately 12.2 μM and the IC50 for
SU11274 to be 4.8 μM (Figure 6). Adding increasing con-
centrations of SU11274 to gefitinib treated cells reduced
the IC50 of the cells to geftinib. CI values were calculated
and values under 1 are considered synergistic. When the
SUM229 cells were treated with gefitinib and SU11274,
the calculated CI values were less than 1. Specifically, at
1.25 μM SU11274 the mean CI value was 0.619 ± 0.038
and at 2.5 μM SU11274 the CI value was 0.781 ± 0.025.
Therefore, EGFR and Met kinase inhibitors interact syn-
ergistically in the SUM229 cells.
Figure 5 EGFR and Met association independent of EGFR kinase 
activity. (A) SUM149 or SUM229 cells were treated with 0.5 μM gefi-
tinib or DMSO control for 30 min. Cells were lysed and immunoprecip-
itated with anti-EGFR, anti-Met, and anti-IgG. Whole cell lysates were 
used as a control. Immunoprecipitates were separated by SDS-PAGE, 
transferred, and immunoblotted using anti-EGFR, anti-Met, or anti-c-
Src antibodies. (B) SUM229 cells were incubated with EGFR shRNA len-
tiviral particles for 72 hrs. Lysates were prepared and separated by SDS-
PAGE. Membranes were immunoblotted with anti-pMet, anti-Met, 
anti-EGFR, and β-actin. (C) SUM229 cells were treated with increasing 
concentrations of dasatinib for 2 hrs. Lysates were prepared and im-
munoblotted with anti-pMet, anti-Met, and anti-pSrc antibodies. (D) 
SUM229 cells were incubated with EGFR shRNA lentiviral particles for 
24 hrs and then treated with puromycin to select for virus expressing 
cells. After the puromycin was added for 24 hrs, the cells were grown 
for 7 days at which point cell numbers were determined via Coulter 
counting.
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We have shown that in an EGFR TKI resistant breast can-
cer cell line, Met was constitutively activated indepen-
dent of ligand. Specifically, HGF was not produced by
these cells and an inhibitory antibody against HGF did
not block Met phosphorylation. This ligand-independent
activation of Met occurred in part by increased Met
expression and in part by association with EGFR. This
association was independent of EGFR kinase activity.
Breaking apart this association by downregulating EGFR
expression dramatically decreased Met phosphorylation
and inhibited cell growth. EGFR also co-precipitated with
c-Src and inhibiting c-Src kinase activity decreased Met
phosphorylation. In addition, inhibiting both EGFR and
Met kinase activities decreased cell viability synergisti-
cally. Therefore, these data demonstrate that an associa-
tion between EGFR, Met, and c-Src regulates Met
constitutive phosphorylation and growth in SUM229
breast cancer cells.
In the mammary gland, HGF is produced in stromal tis-
sue, including mammary fibroblasts, but not in the epi-
thelial cells [20,21]. Therefore, in the mammary gland,
Met is activated by HGF via a paracrine mechanism.
With respect to breast carcinomas, the localization of
HGF within the mammary gland is less clear. Yamashita
and colleagues found that in both human breast tumors
and two breast cancer cell lines, HGF was not expressed
or secreted [22]. In contrast, several groups have sug-
gested that HGF is expressed in the breast tumor cells via
mRNA detection using in situ hybridization [23,24]. In
this study, we demonstrate that HGF protein is not
expressed or secreted in two breast cancer cell lines,
SUM149 and SUM229. These data support the notion
that HGF is primarily produced in stromal tissue in
breast cancers and therefore studying the role of HGF/
Met signaling using cell culture models may overlook
important contributions of the tumor microenvironment
to EGFR/Met crosstalk in breast cancer. In that regard,
we have previously shown that the SUM149 cells
responded to exogenous HGF treatment by phosphory-
lating Met and recovering some EGFR tyrosine phospho-
rylation and growth in the presence of EGFR TKIs [7].
Our data support a ligand-independent mechanism of
Met activation in SUM229 breast cancer cells. Lai and
colleagues summarized multiple mechanisms for ligand-
independent Met activation [14]. Specifically, Met ampli-
fication, mutation, and truncation, overexpression of Met
leading to constitutive dimerization, pathway activation
by hypoxia, transactivation by other receptors, and loss of
negative regulators have been shown to induce ligand-
independent Met activation [14]. Our data clearly dem-
onstrate that Met is not amplified, mutated, or truncated
in SUM229 cells. However, we do find that Met is overex-
pressed at the protein level and that EGFR associates with
Met. We have therefore provided evidence for the inter-
action and dependence of Met phosphorylation by EGFR
expression and kinase activation.
Both physical and functional associations of EGFR and
Met have been described previously. Specifically, EGFR
and c-Met co-associate in normal human hepatocytes
and lung cancer cell lines [25,26]. In a wider array of
models, EGFR and Met have been shown to crosstalk
functionally. EGFR has been shown to activate Met in
lung and thyroid cancer cells as well as in the develop-
ment of the kidney, hepatocytes, and retina [27-32]. This
is the first report of EGFR and Met physically interacting
and EGFR regulating Met activation in the absence of
HGF in breast cancer.
Cellular mechanisms of resistance to EGFR small mole-
cule inhibitors have best been studied in lung cancers
containing EGFR sensitizing mutations. Using clinical
specimens from patients with non small cell lung cancers
that recurred after treatment with EGFR inhibitors, 50%
of patients have acquired an additional mutation, T790
M, which creates an EGFR that no longer responds to
EGFR inhibition [33]. In addition, 20% of EGFR inhibitor
refractory lung cancers have amplification of Met [8,34].
Other molecules such as Ras and IGF-IR also have been
implicated in resistance to EGFR inhibitors [35,36]. The
data provided in this report suggest that in addition to the
identified resistance factors in lung cancer, Met activity
may be a regulator of response to EGFR inhibitors in
breast cancers.
Overall, our data provide evidence for a physical and
functional interaction between EGFR and Met. This
interaction regulates the phosphorylation of both EGFR
Figure 6 EGFR and Met inhibitor synergy in SUM229 cells. 
SUM229 cells were treated with various concentrations of gefitinib and 
SU11274 and the IC50 of gefitinib was calculated for each concentra-
tion of SU11274. A line was drawn between the IC50 for gefitinib (y-axis; 
12.2 μM) and SU11274 (x-axis; 4.8 μM). The calculated IC50 values for ge-
fitinib with SU11274 combination treatment were plotted. Points fall-
ing below the line represent synergistic drug interactions.
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cellular responses independent of EGFR kinase activity.
In addition, this EGFR kinase independent activity is in
part mediated by c-Src activity. Therefore, the abrogation
of the kinase activity of each molecule in combination
provides intriguing evidence for dual EGFR and Met
inhibitor studies in breast cancers.
Materials and methods
Cell lines, culture conditions, and reagents
The growth conditions for each cell line are as follows.
SUM 52, SUM 149, SUM 159, SUM 185, SUM 225, and
SUM 229 cells are grown in 5%IH media (Ham's F-12
media, supplemented with 5% FBS, 1 μg/ml hydrocorti-
sone, and 5 μg/ml insulin). SUM 1315 cells are grown in
5%IE media (Ham's F-12 media, supplemented with 5%
FBS, 10 ng/ml EGF, and 5 μg/ml insulin). SUM 44 and
SUM 190 cells are grown in SFIH media (Ham's F-12
media, supplemented with 1 μg/ml hydrocortisone, 5 μg/
ml insulin, 5 mM ethanolamine, 10 mM HEPES, 5 μg/ml
transferrin, 10 nM triiodo-thyronine, 50 μM sodium sele-
nite, and 5% BSA). SUM 102 and MCF10A cells are
grown in SFIHE media (Ham's F-12 media, supplemented
with 1 μg/ml hydrocortisone, 5 μg/ml insulin, 10 ng/ml
EGF, 5 mM ethanolamine, 10 mM HEPES, 5 μg/ml trans-
ferrin, 10 nM triiodo-thyronine, 50 μM sodium selenite,
and 5% BSA). MCF7, SKBr3, T47 D, MDA-MB-231 and
MDA-MB-468 cells are grown in DMEM+10%FBS media
(DMEM media, supplemented with 10% FBS). BT-20
cells are grown in Eagles+NEAA media (Eagle's MEM
with 2 mM L-glutamine and Earle's BSS adjusted to con-
tain 1.5 g/L sodium bicarbonate, 0.1 mM non-essential
amino acids, 1 mM sodium pyruvate, and 10% FBS). BT-
549 cells are grown in RPMI+L-GLUT(2 mM) media
(RPMI-1640, supplemented to contain 1.5 g/L sodium
bicarbonate, 4.5 g/L glucose, 10 mM HEPES, 1 mM
sodium pyruvate, 0.023 IU/ml insulin, and 10% FBS).
HCC 1937 and HCC 1954 cells are grown in RPMI+L-
GLUT media (RPMI-1640 media with 2 mM L-glutamine
adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L
glucose, 10 mM HEPES, 1 mM sodium pyruvate, and 10%
FBS). The SUM and HCC cells are cultured in 10% CO2
and the remaining cells are cultured in 5% CO2. All media
are supplemented with 2.5 μg/ml amphotericin B and 25
μg/ml genatimicin.
Gefitinib was provided by AstraZeneca, SU11274 was
purchased from EMD Biosciences (Gibbstown, NJ), and
dasatinib was purchased by LC Laboratories (Wouburn,
MA). The HGF neutralizing antibody was a kind gift
from George Vande Woude (VARI, Grand Rapids, MI).
All other reagents were purchased from Thermo Fisher
(Houston, TX) or Sigma (St. Louis, MO), unless indi-
cated.
Genetic analysis
The genomic array CGH experiments were performed
previously using the Agilent 44 K human genome CGH
microarray chip [37,38](Agilent Technologies, Palo Alto,
CA, USA). Circular binary segmentation analysis was
used to determine changes in copy number [39].
HGF ELISA
One million cells were plated on 100 mm dishes and
grown for 48 hours. The media was changed to serum
free media and the cells were incubated for 72 hours.
Conditioned media was collected from fibroblasts engi-
neered to express HGF as a positive control. The HGF
ELSA assay was performed as directed by the manufac-
ture (R&D Systems, Minneapolis, MN). Briefly, condi-
tioned media was undiluted or diluted 1:2 and 1:10 and
used to measure the amount of HGF using a standard
curve.
Immunoprecipitation and Immunoblotting
Cells were plated at 1 million cells per 100 mm dish and
growth for 48 hours. Cells were then lysed in CHAPs lysis
buffer (10 mM CHAPs, 50 mM Tris, pH 8.0, 150 mM
NaCl, and 2 mM EDTA with 10 μM NaOVa and 1× pro-
tease inhibitor cocktail (EMD Biosciences)). For immu-
noprecipitations 500 μg of lysate was precleared with 40
μl of protein A agarose beads (Millipore, Billerica, MA)
for 30 min at 4°C. The supernatant was saved and added
to 5 μl of mab-108 EGFR antibody (kind gift from
Michael Weber, University of Virginia), Met antibody
(Cell Signaling, Beverly, MA), or IgG isotype control anti-
body (Millipore) for 1 hr at 4°C. Immunoprecipitates
were collected with the addition of 40 μl of protein A aga-
rose beads for 30 min at 4°C and washed 2× with CHAPs
and 1× with PBS. The protein was removed from the
beads with 40 μl of hot 2× lameli buffer. Protein was sepa-
rated by SDS-PAGE, transferred to Immunolin-P (Milli-
pore) and immunoblotted for the indicated protein.
For immunoblotting, indicated amount of protein
lysate was separated by SDS-PAGE and transferred to
Immobolin-P. Membranes were blocked in either 5%
non-fat dry milk or 5% BSA for 1 hr at RT. The following
primary antibodies were used in the experiments: anti-
EGFR (Cell Signaling, 1:500), anti-Met (Cell Signaling
1:500), anti-PTyr-HRP (Invitrogen, Carlsbad, CA, 1:5
000), anti-EGFR Y845 (Cell Signaling, 1:750), anti-EGFR
Y992 (Cell Signaling, 1:500), anti-EGFR Y1045 (Cell Sig-
naling, 1:500), anti-EGFR Y1068 (Cell Signaling, 1:500),
anti-EGFR Y1086 (Cell Signaling, 1:500), anti-EGFR
Y1148 (Cell Signaling, 1:500), anti-EGFR Y1173 (Cell Sig-
naling, 1:750), anti-pMet (Cell Signaling, 1:500), anti-
HGF (IBL, 1:500), anti-Src (Cell Signaling,1:1 000), and
anti-β-actin (Sigma, 1:10 000). The antibodies were incu-
bated overnight at 4°C, with the exception of the PTyr
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with antibody for 1 hr. The membranes are then washed
with TBS-T (TBS + 0.1% Tween-2) three times for 10 min
each followed by incubation with the corresponding sec-
ondary antibody, and another series of three washes.
Incubation with enhanced chemiluminescence (GE Bio-
sciences, Piscataway, NJ) followed by exposure to film
was used to detect the reactive bands. Each experiment
was repeated at least three times and quantitated using
densitometry.
Lentiviral shRNA knockdown
To downregulate EGFR and Met expression we used
shRNA lentiviral particles using commercially available
lentiviral constructs from OpenBiosystems (Huntsville,
AL)(EGFR = TRCN0000121204 and Met = TRCN0
000121233). Twenty-four EGFR shRNA constructs and
twelve Met shRNA constructs were screened and vali-
dated for EGFR or Met knockdown. At least three con-
structs were used in the studies for each protein with the
data from the representative shRNA shown. The lentivi-
ruses were packaged using a third generation lentiviral
packaging system developed by Didier Trono and col-
leagues (Lausanne, Switzerland) and purchased from
Addgene [40]. Specifically, Addgene plasmids pMLDg/
pRRE (12251), pRSV-Rev (12253), and pMD2.G (12259)
were transfected into HEK293T cells with the lentiviral
vectors containing the shRNAs using FUGENE6 (Roche,
Madison, WI). Cellular supernatant was collected on days
2 and 3 after transfection, pooled, and filtered. The lenti-
virus was titered using HEK293T cells incubated with
increasing concentrations of virus with polybrene and
selected for via the puromycin selection on the lentiviral
vector. Colonies were counted and used to compare viral
preps and between viruses for consistent titers used in
experiments. For the SUM229 cells, equal amounts of
virus was added to SUM229 cells in the presence of poly-
brene for four days prior to cell lysis.
Cell proliferation assays
For the proliferation assays the indicated breast cancer
cells were plated in triplicate in 6-well plates at 35 000
cells per well (Day 0). The next day, the cells were treated
with gefitinib every day for seven days at the indicated
dosage. The number of cells was determined using a
Coulter Counter on Days 1, 4, and 8. Each experiment
was repeated at least twice and the graph represents the
average and standard error of the mean at day 8.
For the MTS assays, cells were plated at 2 000 cells/well
of a 96 well plate in triplicate. The indicated doses of gefi-
tinib and SU11274 were added 24 hours later. The cells
were incubated with the drugs for 72 hours at which time
the MTS reagent was added per manufacture directions
(Promega, Madison, WI) and read using a Dynex spectro-
photometer. The experiment was repeated three times
with error bars representing the SEM.
Statistics
Isobolograms were performed by determining the IC50
values for gefitinib and SU11274 using Graph Pad Prism
via standard MTS assay. The concentration of gefitinib
used included 0.001, 0.1, 1, 5, 10, 50, and 100 μM. The
concentrations of SU11274 used included 0.01, 0.1, 0.5, 1,
and 5 μM. CI values were calculated using the following
equation: (IC50 combination/IC50 gefitinib) + (concentra-
tion of SU11274/IC50 SU11274). CI values were com-
pared to 1.0 (CI value with 0 μM SU11274) by unpaired T
tests.
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